Agios Pharma Q3 product revenue surges; will have cut 100+ R&D jobs in 2026
Reuters2026/11/05 11:45
Overview
U.S. rare disease drugmaker's Q3 product revenue rose more than fourfold yr/yr, beating analyst expectations
Net loss for Q3 narrowed compared to the prior year
Company cut R&D headcount by over 35% in 2026 to reduce costs
Outlook
Agios targets non-GAAP profitability in 2028
FDA PDUFA goal date for mitapivat in sickle cell disease set for Feb 1, 2027
Company sees expanding AQVESME demand in thalassemia, including non-transfusion dependent patients
Result Drivers
U.S. LAUNCH DEMAND - Co said Q3 revenue growth was driven by U.S. commercial launch of AQVESME in thalassemia and expanding patient demand
EU APPROVAL IMPACT - Ex-U.S. revenue growth attributed to early access programs in Europe after EU approval of PYRUKYND in thalassemia
COMMERCIAL LAUNCH COSTS - Higher SG&A expenses due to increased activity supporting AQVESME launch and preparation for potential mitapivat launch in sickle cell disease
Company press release: ID:nGNXcdNDX2
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q3 Product Revenue |
Beat |
$55.39 mln |
$53.21 mln (10 Analysts) |
Q3 Loss Per Share |
|
$1.09 |
|
Q3 Net Loss |
|
$65.05 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Agios Pharmaceuticals, Inc. is $50.00, about 59.3% above its November 4 closing price of $31.38
Reuters Recommended Reads
Nov 3 - Zevra Therapeutics Q3 revenue rises 45% on MIPLYFFA sales
Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised
Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
